http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCRYST+PHARMACEUTICALS++For%3A+Jun+11/26640844.html si-local-file:///var/storage/secattach/20260612/26640844.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCRYST+PHARMACEUTICALS++For%3A+Jun+11/26640844.html Fri, 12 Jun 2026 16:11:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCRYST+PHARMACEUTICALS++For%3A+Jun+11/26640844.html si-local-file:///var/storage/secattach/20260612/26640844.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCRYST+PHARMACEUTICALS++For%3A+Jun+11/26640844.html Fri, 12 Jun 2026 16:11:00 -0400 BCRX O.00165123 http://www.streetinsider.com/Corporate+News/BioCryst+presents+HAE+treatment+data+at+European+allergy+meeting/26638148.html <p>BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) presented clinical data for its hereditary angioedema treatments at the European Academy of Allergy and Clinical Immunology Annual Meeting in Istanbul from June 12-15.</p><p>The company shared 48-week data from the APeX-P study evaluating ORLADEYO in pediatric HAE patients aged 2 to under 12 years. The median adjusted HAE attack rate requiring on-demand treatment decreased from 0.691 attacks per month during a 12-week standard of care period to 0.169 attacks per month during 48 weeks of ORLADEYO treatment. HAE attacks requiring professional care dropped from 22 during the standard of care period to 3 over 12 http://www.streetinsider.com/Corporate+News/BioCryst+presents+HAE+treatment+data+at+European+allergy+meeting/26638148.html Fri, 12 Jun 2026 07:00:51 -0400 BCRX http://www.streetinsider.com/FDA/BioCryst+presents+HAE+treatment+data+at+European+allergy+meeting/26638148.html <p>BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) presented clinical data for its hereditary angioedema treatments at the European Academy of Allergy and Clinical Immunology Annual Meeting in Istanbul from June 12-15.</p><p>The company shared 48-week data from the APeX-P study evaluating ORLADEYO in pediatric HAE patients aged 2 to under 12 years. The median adjusted HAE attack rate requiring on-demand treatment decreased from 0.691 attacks per month during a 12-week standard of care period to 0.169 attacks per month during 48 weeks of ORLADEYO treatment. HAE attacks requiring professional care dropped from 22 during the standard of care period to 3 over 12 http://www.streetinsider.com/FDA/BioCryst+presents+HAE+treatment+data+at+European+allergy+meeting/26638148.html Fri, 12 Jun 2026 07:00:51 -0400 BCRX http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Press+Releases/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html <p align="center"><strong>— Growing body of ORLADEYO</strong>®<strong> clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations</strong><br/></p> <p align="center"><strong>— New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as </strong><strong>a potential long-acting therapeutic option for the broad HAE population</strong><br/></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jQoNrCAytJQnfDlF2hgFRs38ZLFmK6H58fHci8hoQzoMK7BM34d0ZCamvBggPCm0XR2_Pk2HVKvmiQVBkzF3BZVlpoq1nhBIGvELMYiNsKoB1UBufu6sd8hDqLxAr7oZ" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first http://www.streetinsider.com/Globe+Newswire/BioCryst+Presents+New+Clinical+Data+and+Real-World+Evidence+Demonstrating+Impact+of+HAE+Portfolio+at+the+2026+European+Academy+of+Allergy+and+Clinical+Immunology+Annual+Meeting/26638132.html Fri, 12 Jun 2026 07:00:00 -0400 A.50201579 BCRX O.00165123 O.12524441 http://www.streetinsider.com/Press+Releases/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vS8nc4QnNY7DlP7HtIvepLPHvQzzmnoXRorhCEZCEjUfMEHRJmp3VMEcnLlVzLDZr2uECRY4xxJ0lULXAn1IAd_NhixEOecrEpALqHsWUNdsNHuyCVJvQg-Z5ELFQc0M" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p align="justify">The options http://www.streetinsider.com/Press+Releases/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html Tue, 09 Jun 2026 16:05:00 -0400 BCRX O.00165123 http://www.streetinsider.com/Press+Releases/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vS8nc4QnNY7DlP7HtIvepLPHvQzzmnoXRorhCEZCEjUfMEHRJmp3VMEcnLlVzLDZr2uECRY4xxJ0lULXAn1IAd_NhixEOecrEpALqHsWUNdsNHuyCVJvQg-Z5ELFQc0M" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p align="justify">The options http://www.streetinsider.com/Press+Releases/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html Tue, 09 Jun 2026 16:05:00 -0400 BCRX O.00165123 http://www.streetinsider.com/Globe+Newswire/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vS8nc4QnNY7DlP7HtIvepLPHvQzzmnoXRorhCEZCEjUfMEHRJmp3VMEcnLlVzLDZr2uECRY4xxJ0lULXAn1IAd_NhixEOecrEpALqHsWUNdsNHuyCVJvQg-Z5ELFQc0M" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p align="justify">The options http://www.streetinsider.com/Globe+Newswire/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html Tue, 09 Jun 2026 16:05:00 -0400 BCRX O.00165123 http://www.streetinsider.com/Globe+Newswire/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html <p align="justify">RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vS8nc4QnNY7DlP7HtIvepLPHvQzzmnoXRorhCEZCEjUfMEHRJmp3VMEcnLlVzLDZr2uECRY4xxJ0lULXAn1IAd_NhixEOecrEpALqHsWUNdsNHuyCVJvQg-Z5ELFQc0M" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p align="justify">The options http://www.streetinsider.com/Globe+Newswire/BioCryst+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26623597.html Tue, 09 Jun 2026 16:05:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html si-local-file:///var/storage/secattach/20260602/26591924.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html Tue, 02 Jun 2026 16:16:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html si-local-file:///var/storage/secattach/20260602/26591924.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Milne+Jill+C./26591924.html Tue, 02 Jun 2026 16:16:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html si-local-file:///var/storage/secattach/20260602/26591815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html Tue, 02 Jun 2026 16:14:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html si-local-file:///var/storage/secattach/20260602/26591815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Stonehouse+Jon+P/26591815.html Tue, 02 Jun 2026 16:14:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html si-local-file:///var/storage/secattach/20260602/26591745.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html Tue, 02 Jun 2026 16:11:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html si-local-file:///var/storage/secattach/20260602/26591745.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+McKee+Amy+E/26591745.html Tue, 02 Jun 2026 16:11:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html si-local-file:///var/storage/secattach/20260602/26591677.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html Tue, 02 Jun 2026 16:09:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html si-local-file:///var/storage/secattach/20260602/26591677.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+MILANO+VINCENT/26591677.html Tue, 02 Jun 2026 16:09:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Frank+Steven/26591599.html si-local-file:///var/storage/secattach/20260602/26591599.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOCRYST+PHARMACEUTICALS++For%3A+May+29++Filed+by%3A+Frank+Steven/26591599.html Tue, 02 Jun 2026 16:07:00 -0400 BCRX O.00165123